Compositions and methods for treating precocious puberty

A controlled release reservoir implant containing a formulation comprising (i) histrelin or its pharmaceutically acceptable salt and (ii) stearic acid, the reservoir implant comprising a hydrophilic copolymer obtained from a copolymerization of a mixture comprising about 45% hydroxyethyl methacrylate (HEMA), about 54.5% hydroxypropyl methacrylate (HPMA), and about 0.5% trimethylolpropane trimethacrylate (TMPTMA), and which implant provides a therapeutically effective amount of the histrelin or its pharmaceutically acceptable salt in vivo to improve one or more symptoms of central precocious puberty in a patient, wherein the implant provides an average in vivo release rate between 65 micrograms and 70 micrograms of the histrelin or its salt daily in the patient to maintain a mean plasma concentration of histrelin of about 0.2 ng/ml to about 2 ng/ml over one year.

A controlled release reservoir implant containing a formulation comprising (i) 50 mg histrelin acetate and (ii) stearic acid, the reservoir implant comprising a hydrophilic copolymer obtained from a copolymerization of a mixture comprising about 45% HEMA, about 54.5% HPMA and about 0.5% TMPTMA, and which implant provides a therapeutically effective amount of the histrelin acetate in vivo to improve one or more symptoms of central precocious puberty in a patient, wherein the implant provides an average in vitro release rate of between 65 micrograms and 70 micrograms of the histrelin acetate daily over one year.